Correcting for Discretionary Treatment Crossover in an Analysis of Survival in the Breast International Group BIG 1-98 Trial by Using the Inverse Probability of Censoring Weighted Method-Reference-Cited by-同舟云学术

Correcting for Discretionary Treatment Crossover in an Analysis of Survival in the Breast International Group BIG 1-98 Trial by Using the Inverse Probability of Censoring Weighted Method

Published:2011-03-20 Issue:9 Volume:29 Page:1093-1095
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Finkelstein Dianne M.¹,Schoenfeld David A.¹

Affiliation:

1. Massachusetts General Hospital and Harvard University, Boston, MA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2010.33.9374

Reference4 articles.

1. Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study

2. Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer

3. Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log-Rank Tests

4. Sensitivity analysis for the estimation of rates of change with non-ignorable drop-out: an application to a randomized clinical trial of the vitamin D3

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy;Cancer Medicine;2016-01-27

2. A Multi-State Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression;Statistics in Biopharmaceutical Research;2016-01-02

3. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial;Journal of Clinical Oncology;2015-09-01

4. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS);Annals of Oncology;2015-08

5. Intraperitoneal Chemotherapy: Long-Term Outcomes Revive a Long-Running Debate;Journal of Clinical Oncology;2015-05-01